BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Acquired flavors producer Tastemaker (2/97)
Acquired Corange group (Boehringer Mannheim and DePuy) (3/98),
received approval from U.S. FTC to acquire Corange on condition that
Roche not acquire dominant position in the thrombolytics market, Roche
also agreed to sell rights to Retevase to Centocor Inc. (2/98)
Sold DePuy to Johnson & Johnson (7/98)
Changed name from F. Hoffmann-La Roche to Roche Holding Ltd. (8/00)
Roche alliance with Chugai (Japan), majority shareholders--50.1% (10/02)
Acquired Disetronic and Igen (2003)
Acquired GlycoArt Biotechnology AG (7/05)
Member--Biotechnology Industry Organization
FACILITIES: Facilities in Switzerland and more than 50 countries worldwide
Expanding research and production facilities
STOCK-FINANCIAL HISTORY: Shares and nonvoting equity securities are listed on the Basel, Zurich and
Geneva stock exchanges
Sales CHF35.511b (YE 05) compared to CHF29.522b (YE 04)
Net income CHF6.730b (YE 05) compared to CHF7.063b (YE 04)
Earnings per share CHF7.68/share (YE 05) compared to CHF5.72/share
(YE 04)
SUBSIDIARIES/DIVISIONS: American subsidiaries include:
Hoffmann-La Roche Inc.--Nutley, N.J.
American Roche International Inc.--Clifton, N.J.
Genentech Inc.
Roche Holdings Inc.--Dover, Del.
Roche Diagnostic Systems Inc.--Indianapolis, Ind.
Roche Molecular Systems Inc.--Pleasanton, Calif.
Roche Professional Service Centers Inc.--Paramus, N.J.
Roche Bioscience
Divisions: pharmaceuticals, diagnostics
INVESTMENTS: Laboratory Corp. of America
Genentech--about 66%
Foundations:
Roche Research Foundation, Basel (1996)
Roche Organ Transplant Research Foundation--$16.5M (7/98)
BUSINESS STRATEGY: Focus on health care, especially innovative drugs, biotech products, and
molecular diagnostics
Invest in own research and form strong relationships with biotech companies
and universities
Use synergies between diagnostics and drug development to offer
integrated health care solutions
AGREEMENTS: Name Products Content of Agreement Date
454 Life Sciences development,
exclusive five-year 5/05
promotion, sale and worldwide
distribution of 454's
Genome Sequencing
Systems
agreement
Actelion Ltd. development and
commercialization of
Actelion's selective
S1P1 receptor agonist
Affymetrix Inc. Genechip technology
for research in
genomics
exclusive
worldwide
collaboration
research
agreement--joint
development
agreement through
Roche Molecular
Systems
Copyright ©2006 AHC Media ® 160
7/06
12/95
Alanex Corp. screening libraries 4/97
Ambit Biosciences Ambit's kinase-
licensing
8/04
Corp.
screening platform agreement